Home Featured Page 9

Featured

Latest

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

February 2025 Psychedelic Patent Update: Terran Secures New Overlapping IP; Porta...

Beyond Guinea Pigs: Ensuring Access to Psychedelic Therapies for Europeans

SoundMind Institute – Dr Hannah McLane

Pα+ Psychedelic Bulletin #191: Psychedelics at SXSW; Swiss Study Finds No...

Behind the Scenes of the “Psychedelic Renaissance” at SXSW 2025

Inside the World’s Most Active Psychedelic Therapy Site: A Conversation with...

Erica Siegal LCSW – NEST and SHINE Collective

LIVESTREAM: Alaska Natural Medicine

Pα+ Psychedelic Bulletin #190: ‘Europe’s Most Feared Investor’ Teams Up with...

1...8910...291 Page 9 of 291

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

February 2025 Psychedelic Patent Update: Terran Secures New Overlapping IP; Porta...

Beyond Guinea Pigs: Ensuring Access to Psychedelic Therapies for Europeans

SoundMind Institute – Dr Hannah McLane

Natural Medicine Alaska

Pα+ Psychedelic Bulletin #191: Psychedelics at SXSW; Swiss Study Finds No...

Behind the Scenes of the “Psychedelic Renaissance” at SXSW 2025

Inside the World’s Most Active Psychedelic Therapy Site: A Conversation with...

Erica Siegal LCSW – NEST and SHINE Collective

LIVESTREAM: Alaska Natural Medicine

Pα+ Psychedelic Bulletin #190: ‘Europe’s Most Feared Investor’ Teams Up with...

EDITOR PICKS

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY